24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
What People With Sickle Cell Disease Need to Know About COVID-19Evidence Mounts That TB Vaccine Might Help Protect Against COVID-19New Coronavirus Cases and Deaths Spike Across AmericaHigh-Fiber, Low-Fat Diet May Help People With Ulcerative ColitisRemdesivir May Reduce Deaths, Hasten Recovery for COVID-19 PatientsAHA News: More People Are Dying During the Pandemic – and Not Just From COVID-19Antiviral Drugs Tied to Heart Issue in COVID-19 PatientsMost Survivors of Severe COVID-19 Report Symptoms Many Weeks After 'Recovery'Terrifying Delirium Can Strike Hospitalized COVID-19 PatientsCold War Antiseptic May Be Valuable Germ FighterWith Social Distancing, Schools Should Be Safe to Reopen This Fall, Experts SayU.S. Sees Another Record-Breaking Day of New Coronavirus Cases'Aerosol Boxes' Meant to Protect COVID Health Teams Might Harm Them: StudyAHA News: Where Do New Viruses Like the Coronavirus Come From?Blood Test May Reveal Concussion Severity With Accuracy of Spinal TapIn Many Cases, Hip Replacement Also Eases Back Pain'Broken Heart Syndrome' Has Risen During Pandemic: StudyCoronavirus Fears Kept Many Essential Workers at Home in April: StudyExposure to Iodine in the NICU May Affect Infant Thyroid FunctionA Dangerous Antibiotic-Resistant Bacteria May Now Lurk in U.S. Water, SoilZika May Have Damaged More Infants' Brains Than ExpectedU.S. Air Pollution Still at Deadly Levels, Study FindsCOVID-19 Outbreaks at Meat Processing Plants Are Hitting Minorities HardU.S. Coronavirus Cases Near 3 Million as Hospitals in Sun Belt Fill Up With PatientsAHA News: Months After Infection, Many COVID-19 Patients Can't Shake IllnessCoronavirus Ups Anxiety, Depression in the LGBTQ CommunityMajor Medical Groups Urge Americans to Wear Face MasksBlack Patients Fare Worse After AngioplastyHow Immune System Fights COVID-19 May Be Key to Vaccine SuccessWill the COVID-19 Pandemic Leave a Mental Health Crisis in Its Wake?New U.S. Coronavirus Cases Hit Another HighMultiple Surgeries for Cleft Lip, Palate Won't Cause Major Psychological DamageHIV May Not Worsen COVID-19 OutlookU.S. Coronavirus Hospitalizations Spiking in South, WestAHA News: To Everything There Is a Season, Including Heart DiseaseAsthma, Allergies Plus Pandemic May Pose 4th of July ChallengesStroke Appears 8 Times More Likely With COVID Than With FluCOVID-19 Death Risk Twice as High in New York City as Some CountriesFireworks Are Bad News for Your LungsScientists Find Source of COVID ClotsNew U.S. Coronavirus Cases Top 50,000 as More States Slow Reopening PlansNumbers of Non-COVID-19 Deaths Up During PandemicNo Good Evidence on Accuracy of Coronavirus Antibody Tests: StudyAHA News: COVID-19 Pandemic Brings New Concerns About Excessive DrinkingMuscle Relaxants for Back Pain Are Soaring: Are They Safe?Trauma of Racism Fuels High Blood Pressure Among Black Americans: StudyCOVID-19 Blood Test Might Predict Who Will Need a VentilatorWhat's the Best DIY Face Mask Against COVID-19?Deep Brain Stimulation May Slow Parkinson's, Study FindsU.S. Could See 100,000 New Cases of COVID-19 Each Day, Fauci Says
Questions and AnswersLinks
Related Topics

Diabetes

FDA Approves First Contact Lens That Slows Myopia Progression


HealthDay News
Updated: Nov 18th 2019

new article illustration

MONDAY, Nov. 18, 2019 (HealthDay News) -- MiSight, the first contact lens indicated to slow the progression of myopia in children ages 8 to 12 years, has been approved by the U.S. Food and Drug Administration, the agency announced Friday.

The single-use, disposable, soft contact lenses should be discarded after one-day use and are not intended to be worn overnight. They are indicated to correct and slow progression of myopia in children with healthy eyes, the FDA noted. Like a standard corrective lens, one part of the MiSight contact lens corrects the refractive error to improve distance vision. Concentric peripheral rings in the lens also focus part of the light in front of the retina to reduce the stimulus causing myopia progression.

The FDA approved MiSight based on data from a prospective clinical trial at four clinical sites and real-world evidence. Safety and effectiveness of MiSight were demonstrated in a three-year randomized, controlled clinical trial of 135 children ages 8 to 12 years old at the start of treatment with MiSight or a conventional soft contact lens. During the entire three years, children who wore MiSight lenses had less progression of myopia compared with those who wore conventional soft contact lenses. Researchers also found that children who wore MiSight lenses had less change in the axial length of the eyeball at each yearly checkup. No serious ocular adverse events were reported for any patients.

The FDA also reviewed real-world data from a retrospective analysis of medical records of 728 children aged 8 to 12 years old from seven community eye care clinics. Data showed a similar rate of corneal ulcer cases in children who wore MiSight as in adults who wear contact lenses daily.

Approval was granted to CooperVision.

More Information